Vaccines for the prevention of diseases caused by potential bioweapons

被引:25
作者
Hassani, M
Patel, MC
Pirofski, LA
机构
[1] Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA
[2] Montefiore Med Ctr, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
bioterror; anthrax; smallpox; plague; tularemia; Q fever; viral hemorrhagic fever; vaccine; toxin; category A agents;
D O I
10.1016/j.clim.2003.09.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of vaccines and implementation of vaccination programs are among the most important medical contributions to humanity. To date, vaccination has reduced morbidity and mortality from infectious diseases more than any other specific medical intervention. The intentional use of bioweapons against civilians (bioterrorism), recently highlighted by events around the world, has fueled interest in the development of vaccines for potential microbial agents of bioterror. This review discusses the microbial agents that are considered to pose the greatest risk to the public, the diseases associated with them, and the vaccines that are available for their prevention. The paucity of such vaccines and uncertainty regarding mechanisms of vaccine efficacy and the microbial antigens that elicit protection underscore the need for continued study of host-microbe interaction and the immune response to potential agents of bioterror for the development of new vaccines and immune-based therapies to combat their potential to harm the public. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 110 条
[81]  
Phillpotts RJ, 2000, ACTA VIROL, V44, P233
[82]   Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus [J].
Phillpotts, RJ ;
Jones, LD ;
Howard, SC .
VACCINE, 2002, 20 (11-12) :1497-1504
[83]   Anthrax as a potential biological warfare agent [J].
Pile, JC ;
Malone, JD ;
Eitzen, EM ;
Friedlander, AM .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (05) :429-434
[84]  
Pirofski LA, 1998, CLIN MICROBIOL REV, V11, P1
[85]   Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens [J].
Pirofski, LA .
TRENDS IN MICROBIOLOGY, 2001, 9 (09) :445-451
[86]  
Ramírez JC, 2002, J GEN VIROL, V83, P1059, DOI 10.1099/0022-1317-83-5-1059
[87]   Reverse vaccinology, a genome-based approach to vaccine development [J].
Rappuoli, R .
VACCINE, 2001, 19 (17-19) :2688-2691
[88]   Developing new smallpox vaccines [J].
Rosenthal, SR ;
Merchlinsky, M ;
Kleppinger, C ;
Goldenthal, KL .
EMERGING INFECTIOUS DISEASES, 2001, 7 (06) :920-926
[89]   A COMPARISON OF PLAGUE VACCINE, USP AND EV76 VACCINE-INDUCED PROTECTION AGAINST YERSINIA-PESTIS IN A MURINE MODEL [J].
RUSSELL, P ;
ELEY, SM ;
HIBBS, SE ;
MANCHEE, RJ ;
STAGG, AJ ;
TITBALL, RW .
VACCINE, 1995, 13 (16) :1551-1556
[90]   TULAREMIA VACCINE STUDY .2. RESPIRATORY CHALLENGE [J].
SASLAW, S ;
WILSON, HE ;
CARHART, S ;
EIGELSBACH, HT ;
PRIOR, JA .
ARCHIVES OF INTERNAL MEDICINE, 1961, 107 (05) :702-+